Article
Debu Tripathy Discusses a Clinical Trial of Ibrance in Breast Cancer
Author(s):
Debu Tripathy, editor-in-chief of CURE and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses adding the targeted drug Ibrance to the hormonal drug Faslodex.
Debu Tripathy, editor-in-chief of CURE and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses adding the targeted drug Ibrance to the hormonal drug Faslodex.
This trial, of women with previously treated hormone receptor-positive, HER2-negative breast cancer, was presented during the 2015 annual meeting of the American Society of Clinical Oncology, a gathering of nearly 30,000 oncology professionals taking place in Chicago.
Read more about the trial here.
